Canopy Growth Corp (TSE:WEED – Get Free Report) was down 0.8% during trading on Friday . The stock traded as low as C$1.27 and last traded at C$1.28. 304,575 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,644,805 shares. The stock had previously closed at C$1.29.
Analysts Set New Price Targets
Separately, Alliance Global Partners cut their price target on Canopy Growth from C$1.80 to C$1.60 in a report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Canopy Growth has an average rating of “Moderate Buy” and a consensus price target of C$1.88.
Get Our Latest Analysis on WEED
Canopy Growth Price Performance
Canopy Growth (TSE:WEED – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported C($0.03) earnings per share for the quarter. The company had revenue of C$81.17 million during the quarter. Canopy Growth had a negative return on equity of 29.85% and a negative net margin of 73.95%. On average, research analysts expect that Canopy Growth Corp will post -0.69 earnings per share for the current fiscal year.
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.
Featured Stories
- Five stocks we like better than Canopy Growth
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
